Table 1.
Characteristics of HC and AD/MCI subjects
| Characteristic | HC (n = 276) | AD/MCI (n = 387) (nAD = 119; nMCI = 268) |
|---|---|---|
| Age, mean (SD) | 73 (6) | 73 (7) |
| Baseline MMSE, mean (SD) | 29 (1) | 26 (3) |
| No. (%) APOEε4 carriers | 82 (30) | 266 (69) |
| No. (%) male | 128 (46) | 215 (56) |
| No. with CSF Aβ42 data (baseline, 24 months, 48 months) | 242, 126, 37 | 357, 137, 40 |
| No. with CSF p-tau data; baseline, 24 months, 48 months | 242, 126, 37 | 357, 137, 40 |
| No. with 18F-AV-45 PET data; baseline, 24 months, 48 months) | 271, 207, 129 | 387, 195, 86 |
| No. amyloid positive/no. amyloid negative at baseline* | 100/171 | 387 |
-
AD/MCI subjects were PET-confirmed to be above the amyloid positivity cutoff.
-
↵*271 of 276 HC subjects had baseline amyloid PET scans, 100 of whom were amyloid-positive.
